Opioid use among low back pain patients in primary care: Is opioid prescription associated with disability at 6-month follow-up? by Ashworth, J et al.
www.e l sev ie r . com/ loca te /pa in
PAIN

154 (2013) 1038–1044Opioid use among low back pain patients in primary care: Is opioid
prescription associated with disability at 6-month follow-up?
Julie Ashworth a,b,c,⇑, Daniel J. Green a, Kate M. Dunn a, Kelvin P. Jordan a
aArthritis Research UK Primary Care Centre, Keele University, Staffordshire, UK
b IMPACT Community Pain Service, Staffordshire & Stoke-on-Trent Partnership Trust, Staffordshire, UK
cUniversity Hospital of North Staffordshire, Stoke-on-Trent, Staffordshire, UK
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.a r t i c l e i n f o
Article history:
Received 9 August 2012
Received in revised form 17 December 2012
Accepted 7 March 2013
Available online xxxx
Keywords:
Disability
Low back pain
Opioids
Propensity score
Prospective cohort0304-3959  2013 International Association for the S
http://dx.doi.org/10.1016/j.pain.2013.03.011
⇑ Corresponding author. Address: Arthritis Resear
Primary Care Sciences, Keele University, Staffordshire
734887; fax: +44 01782 733911.
E-mail addresses: j.ashworth@cphc.keele.ac
(J. Ashworth).
URL: http://www.keele.ac.uk/pchs/ (J. Ashworth).a b s t r a c t
Opioid prescribing for chronic noncancer pain is increasing, but there is limited knowledge about longer-
term outcomes of people receiving opioids for conditions such as back pain. This study aimed to explore
the relationship between prescribed opioids and disability among patients consulting in primary care
with back pain. A total of 715 participants from a prospective cohort study, who gave consent for review
of medical and prescribing records and completed baseline and 6 month follow-up questionnaires, were
included. Opioid prescription data were obtained from electronic prescribing records, and morphine
equivalent doses were calculated. The primary outcome was disability (Roland-Morris Disability Ques-
tionnaire [RMDQ]) at 6 months. Multivariable linear regression was used to examine the association
between opioid prescription at baseline and RMDQ score at 6 months. Analyses were adjusted for poten-
tial confounders using propensity scores reﬂecting the probability of opioid prescription given baseline
characteristics. In the baseline period, 234 participants (32.7%) were prescribed opioids. In the ﬁnal mul-
tivariable analysis, opioid prescription at baseline was signiﬁcantly associated with higher disability at 6-
month follow-up (P < .022), but the magnitude of this effect was small, with a mean RMDQ score of 1.18
(95% conﬁdence interval: 0.17 to 2.19) points higher among those prescribed opioids compared to those
who were not. Our ﬁndings indicate that even after adjusting for a substantial number of potential con-
founders, opioids were associated with slightly worse functioning in back pain patients at 6-month fol-
low-up. Further research may help us to understand the mechanisms underlying these ﬁndings and
inform clinical decisions regarding the usefulness of opioids for back pain.
 2013 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY-NC-ND license. 1. Introduction harms. A Danish study found that opioid use for chronic pain wasOpioid prescribing for chronic noncancer pain has increased in
recent years [6], and chronic low back pain (LBP) is among the
most common nonmalignant disorders associated with prescribed
opioid use in primary care [1,26]. Although opioids are an accepted
treatment for LBP, there is limited evidence of their efﬁcacy
[7,9,18,19]. The evidence is largely derived from randomized con-
trolled trials with short-term (616 weeks) follow-up, in highly se-
lected populations, and functional outcomes are considered only in
a minority of studies. In addition to the uncertainty around efﬁ-
cacy, the epidemiological literature raises concern about potentialtudy of Pain. Published by Elsevie
ch UK Primary Care Centre,
, UK ST5 5BG. Tel.: +44 01782
.uk, ashworth@keele.ac.uksigniﬁcantly associated with reporting of severe pain, poor self-
rated health, unemployment, higher health care use, and lower
self-rated quality of life [11]. In the United States, Kidner et al.
[17] reported that patients with chronic musculoskeletal pain
who were taking opioids reported higher pain severity, greater dis-
ability, and higher levels of depression compared with those who
were not. Saunders et al. [29] reported a twofold increase in the
fracture risk for older patients prescribedP50 mg daily morphine
equivalent dose (MED), and Dunn et al. [10] reported an increasing
incidence of accidental overdose with increasing strength of pre-
scribed opioids.
Two previous studies [14,36] explored the relationship between
prescribed opioids and disability in acute LBP and reported an
association between early prescription of opioids for LBP and high-
er long-term disability in U.S. workers’ compensation claimants. A
Canadian study [15] looked at the relationship between opioid pre-
scribing and continued disability in a broader range of painful
musculoskeletal conditions and also reported that, after adjustingr B.V. Open access under CC BY-NC-ND license. 
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were less likely to return to work. However, this study identiﬁed
a similar association with receipt of an early prescription for non-
steroidal anti-inﬂammatory drugs (NSAIDs) and muscle relaxants,
raising the possibility of confounding by indication. Given the con-
siderable overlap in the factors inﬂuencing LBP-related disability
and opioid use, there are a number of potential confounders, many
of which could not be adjusted for in these studies. Both long-term
disability and opioid use have previously been reported to be asso-
ciated with baseline disability [30,32], radiculopathy [30,32], and a
number of psychosocial factors [4,8,31]. There are conﬂicting re-
ports about the inﬂuence of pain intensity on both disability [5,8]
and opioid use [12,31]. Furthermore, previous studies in this ﬁeld
are conﬁned to populations of workers in North America, using
continued receipt of wage replacement beneﬁts as a surrogate
measure of disability, and the generalizability of the ﬁndings out-
side this population is uncertain.
This study sought to assess the relationship between opioid
prescribing at baseline and self-reported disability, as measured
by the Roland and Morris Disability Questionnaire (RMDQ), at 6-
month follow-up in a UK population of primary care consulters
with LBP. We used a propensity score approach to adjust for a sub-
stantial number of important potential confounders in the rela-
tionship between opioid use and disability.Fig. 1. Flow chart. Foster et al., 2008 [13].2. Methods
This study is a secondary analysis nested in a prospective cohort
study of patients consulting in UK primary care with LBP (the Be-
Back study). Ethical approval for the BeBack study was obtained
from the North Staffordshire and Central Cheshire Research Ethics
Committees.
2.1. Population and study design
The original study recruited 1591 patients ages 18 to 60 years
consulting in primary care with LBP between September 2004
and April 2006. Full details of this study are available elsewhere
[13]. Study participants received postal questionnaires at baseline
(soon after their index consultation) and 6 months later. For nonre-
sponders, a reminder postcard was sent after 2 weeks with a re-
minder questionnaire after 4 weeks. Participants’ consent to
review of their medical records was also requested. Electronic pre-
scribing records for consenting study participants were obtained as
part of the medical record information from the primary care prac-
tices participating in the BeBack study, for the period between
recruitment (from September 2004 to April 2006) and 6-month fol-
low-up. As part of the Keele GP Research Partnership, these prac-
tices participate in regular training and audit to ensure the
quality of data recording [25].
A total of 1224 (77%) patients in the original cohort gave con-
sent for review of medical and prescribing records. Of these, 715
(58%) completed a 6-month follow-up questionnaire and were in-
cluded in this nested study, as shown in Fig. 1. The potential for
nonresponse bias due to loss of follow-up was addressed in the ori-
ginal study through comparisons of the baseline characteristics of
responders and nonresponders, and the baseline data for employ-
ment status, symptom duration, and RMDQ score were almost
identical [13].
2.2. Measures
2.2.1. Opioid prescription
Data regarding prescribed opioids were obtained from elec-
tronic prescribing records. Back pain consulters were identiﬁedfrom participating practices on a weekly basis, and baseline ques-
tionnaires were sent in the week after consultation. To ensure
inclusion of prescribing data from the time of the index consulta-
tion, the baseline period for this study was deﬁned as the 28-day
period starting 14 days before the date the baseline questionnaire
was sent. Baseline opioid use was deﬁned as receipt of 1 or more
prescriptions for an opioid analgesic in the baseline period. The
duration of opioid therapy prior to the baseline period was un-
known. The total opioid medication prescribed in the baseline per-
iod was obtained by multiplying the total number of tablets or
patches prescribed in the 28-day period by the dose of each tablet
or patch. This was then converted to an MED using previously pub-
lished equianalgesic conversion factors [35]. Average daily MED
was then calculated by dividing the total MED prescribed in the
baseline period by 28 and classiﬁed into 4 dose groups
(none = 0 mg/d, low = 1 to 19 mg/d, medium = 20 to 49 mg/d, and
high =P50 mg/d) based on previously published work [29].
2.2.2. Outcomes
The RMDQ [27] was used to measure self-reported disability. It
includes 24 items and is scored from 0 (no disability) to 24 (highest
1040 J. Ashworth et al. / PAIN
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ported disability based on RMDQ from the 6-month follow-up
questionnaire.
2.2.3. Baseline covariates (potential confounders)
Baseline variables with the potential to affect disability (RMDQ)
at follow-up based on theoretical considerations and the published
literature were included as potential confounders. Sociodemo-
graphic information including age, gender, socioeconomic status
(based on job title) [21,22], education, employment status, and
work loss due to back pain was obtained at baseline.
In addition to RMDQ, usual pain intensity on a 0 (no pain) to 10
(worst pain) numerical rating scale, duration of symptoms, and
presence of leg pain below the knee were also reported on the
questionnaire.
From the prescribing records, information was obtained regard-
ing baseline NSAID use, deﬁned as receipt of 1 or more prescrip-
tions for an NSAID in the baseline period (deﬁned as for opioid
medication), and a count of all prescribed nonopioid medications
in the same period was used as a surrogate measure for comorbid-
ity [24].
A range of psychological measures were included in the ques-
tionnaires: The Hospital Anxiety and Depression Scale (HADS)
[38] provides subscale scores from 0 to 21 for anxiety and depres-
sion. Given that anxiety and depression are frequently highly cor-
related, we merged these 2 variables to facilitate more efﬁcient
adjustment for confounding. We used the established cut-off of 8
on each subscale to indicate likely depression or anxiety [3] to cat-
egorize patients into 3 groups for distress dependent on whether
they had a HADS score of P8 for both depression and anxiety, a
score of P8 for either depression or anxiety, or a score of <8 on
both anxiety and depression. Fear of movement was assessed usingTable 1
Baseline characteristics by opioid prescription status (n = 715).
No opioid prescri
None
Baseline characteristic n = 481(67.3%)
Age (years), mean (SD) 45.77 (9.87)
Gender, female 56.1%
Socioeconomic status
Professional/manager
33.7%
Employment status
Employed and working as usual
63.4%
Duration of current episode of lower back pain
>3 months
34.3%
Leg pain below the knee 32.0%
Usual pain intensity
Numerical rating scale (0–10), mean (SD)
4.28 (2.49)
Disability
Roland-Morris Disability Questionnaire (0–24), mean (SD)
7.37 (5.18)
Distress
Hospital Anxiety and Depression
Questionnaire score P8 for anxiety and depression
26.2%
Fear of movement
Tampa Scale of Kinesiophobia (17–68), mean (SD)
38.70 (6.83)
Self efﬁcacy
Pain Self-Efﬁcacy Questionnaire (0–60), mean (SD)
41.60 (12.79)
Coping style
CSQ—diversion (0–36), mean (SD) 14.98 (8.15)
CSQ—catastrophizing (0–36), mean (SD) 8.64 (6.93)
CSQ—reinterpretation (0–36), mean (SD) 7.63 (6.98)
CSQ—cognitive coping (0–30), mean (SD) 17.56 (6.12)
Nonsteroidal anti-inﬂammatory drug
Prescribed at baseline
32.0%
Comorbidity
Number of prescribed nonanalgesic medications, mean (SD)
0.88 (1.64)
CSQ = Coping Strategies Questionnaire.
* Comparison of any opioid prescription at baseline versus no opioid prescription at bathe Tampa Scale of Kinesiophobia [34]. This comprises 17 items,
each scored on a 4-point Likert scale (range of scores: 17 to 68);
higher scores indicate greater levels of fear avoidance. Coping style
was assessed using the 4 subscales of the Coping Strategies Ques-
tionnaire [16], with higher scores on each subscale indicating high-
er frequency of the speciﬁc coping style: catastrophizing (6 items;
subscale score: 0 to 36), diversion (6 items; 0 to 36), reinterpreta-
tion (6 items; 0 to 36), and cognitive coping (5 items; 0 to 30). We
used the Pain Self-Efﬁcacy Questionnaire [20] to assess patients’
beliefs about their ability to accomplish activities despite pain. It
has 10 items, each with a 6-point Likert scale (scale score: 0 to
60), and higher scores indicate stronger self-efﬁcacy beliefs.
2.3. Statistical analyses
Initial analyses were carried out to explore the unadjusted rela-
tionship between receipt of an opioid prescription in the baseline
period and disability (RMDQ score) at 6 months. We then adjusted
solely for baseline RMDQ score because baseline disability is likely
to be the strongest determinant of disability at follow-up [8,32,33].
For comparison, we also explored the relationship between receipt
of an NSAID prescription in the baseline period and disability at
6 months in order to ascertain whether any association observed
between opioids and future disability was also observed with other
prescribed analgesics and therefore likely to be due to a general
association with analgesic medication. The main analysis was con-
ﬁned to investigating the effect of receiving an opioid prescription
(yes or no). We had also intended to investigate the effect of opioid
dose on disability, but were unable to do so due to the small num-
bers in the higher-dose opioid groups.
Propensity scores are a statistically efﬁcient method of adjust-
ing for multiple confounding factors. Using this method permitsption Opioid prescription group (morphine equivalent dose) t test/v2
P value*
Low Medium High
n = 152(21.3%) n = 57(8.0%) n = 25(3.5%)
46.27 (9.36) 44.07 (10.69) 47.64 (9.39) .891
67.1% 73.7% 76.0% <.001*
26.3% 26.4% 24.0% .022*
40.8% 26.3% 24.0% <.001*
34.9% 43.9% 36.0% .450
39.5% 49.1% 68.0% .001*
5.43 (2.66) 6.21 (2.25) 7.08 (2.31) <.001*
10.74 (5.99) 13.05 (5.99) 15.56 (5.21) <.001*
36.8% 50.9% 56.0% <.001*
40.32 (6.78) 41.01 (6.72) 42.97 (7.12) <.001*
34.05 (14.96) 27.97 (15.26) 26.84 (13.23) <.001*
16.53 (6.50) 16.31 (6.59) 18.92 (6.65) .008*
11.05 (8.35) 13.31 (9.23) 16.5 (8.98) <.001*
7.60 (6.49) 6.94 (6.50) 7.50 (5.20) .714
15.84 (6.50) 15.70 (6.59) 15.48 (5.87) <.001*
49.3% 43.9% 48.0% <.001*
2.05 (3.12) 2.35 (3.75) 3.28 (3.54) <.001*
seline.
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(the propensity score), which reﬂects the probability of an individ-
ual receiving an opioid prescription given their baseline character-
istics. Linear regressions were performed for each baseline
covariate separately with RMDQ at follow-up as the dependent
variable to identify the extent of the unadjusted association of
these potential confounders with RMDQ at 6 months.
The propensity score was then estimated using a logistic regres-
sion model with opioid prescription status (yes or no) as the
dependent variable and all baseline covariates as the explanatory
variables. The propensity to receive an opioid at baseline was cal-
culated for all participants, and participants were divided into 5
groups based on the quintile propensity scores. Checks were per-
formed to ensure balance within the 5 propensity groups between
those who did receive an opioid and those who did not; this was
performed by checking that within each group, the distribution
of baseline variables was comparable for participants who were
and were not prescribed an opioid during the study baseline peri-
od. In the event of an imbalance for particular variables, an inter-
action term was introduced for these variables in the propensity
model in an attempt to obtain improved balance within groups.
In the event of imbalance once interaction terms had been investi-
gated, the remaining variables were included as an independent
predictor of the outcome, along with the propensity score and opi-
oid status. Multivariable linear regression was then used to exam-
ine the association between prescription of an opioid in the
baseline period and disability as measured by RMDQ at 6-month
follow-up, adjusting for propensity score group.
3. Results
In the baseline period, 234 of the 715 participants (32.7%) were
prescribed opioids. For those prescribed opioids, the mean daily
MED was 22.74 mg (SD 31.57) and the median daily opioid dose
was 16.07 mg (interquartile range 5.36 to 26.70). When classiﬁed
according to average daily MED, the majority, 152 (21.3% of the
study population), were prescribed low dose (1 to 19 mg MED/
day), 57 (8.0%) medium dose (20 to 49 mg MED/day), and 25
(3.5%) high dose (P50 mg MED/day) opioids.
The baseline characteristics of the study participants, according
to their opioid prescription status, are shown in Table 1. Patients
prescribed any dose of opioid in the baseline period had higher
mean usual pain intensity (P < .001), had higher disability on
RMDQ (P < .001), and were more likely to report higher distress
(anxiety and depression scoresP8 on HADS scale) (P 6 .001), low-
er self-efﬁcacy (P < .001), greater fear of movement (Tampa Scale of
Kinesiophobia P < .001), and a greater tendency to catastrophize
(Coping Strategies Questionnaire-catastrophizing P < .001) at base-Table 2
Changes between baseline and follow-up by opioid prescription status.
No opioid
Baseline s
Disability
Roland-Morris Disability Questionnaire* (0–24), mean (SD)
7.37 (5.1
Usual pain intensity
Numerical Rating Scale* (0–10), mean (SD)
4.27 (2.5
Depression
Hospital Anxiety and Depression Questionnaire* (0–21), mean (SD)
5.69 (3.7
Anxiety
Hospital Anxiety and Depression Questionnaire* (0–21), mean (SD)
7.83 (4.2
Self-efﬁcacy
Pain Self-Efﬁcacy Questionnaire (0–60), mean (SD)
41.60 (12
* Lower score indicates improvement.
 Higher score indicates improvement.line compared with those who were not prescribed opioids. Among
those prescribed opioids, the mean reported levels of pain, disabil-
ity, and distress increased from the low-dose to the high-dose
groups, as did the score for catastrophizing. Self-efﬁcacy scores
were lower in the higher dose groups. Those prescribed opioids
were also signiﬁcantly more likely to receive an NSAID prescription
and had signiﬁcantly greater comorbidity scores, with the highest
comorbidity scores in the high-dose group. There was no signiﬁ-
cant difference in terms of mean age, but the proportion of female
patients was signiﬁcantly greater in those receiving an opioid pre-
scription, particularly in the higher dose groups.
Across the study population, self-reported disability, pain, self-
efﬁcacy, anxiety, and depression showed some improvement dur-
ing the 6-month follow-up period; the degree of improvement
was similar for those who were prescribed opioids in the baseline
period and those who were not (Table 2).
Results of unadjusted regression analyses demonstrating the
relationship between all of the baseline characteristics and RMDQ
score at 6 months are given in Table 3. Receipt of an opioid pre-
scription at baseline predicted a higher RMDQ score at 6 months
in the unadjusted regression analysis (coefﬁcient = 4.21, 95% conﬁ-
dence interval [CI] 3.28 to 5.14). This remained signiﬁcant after
adjusting for baseline RMDQ score (Table 4), although the coefﬁ-
cient was reduced (coefﬁcient = 1.23, 95% CI 0.45 to 2.00). Receipt
of an NSAID prescription in the baseline period was not signiﬁ-
cantly associated with RMDQ score at follow-up in the unadjusted
analysis (coefﬁcient = 0.33 95% CI 0.62 to 1.28, P = .50).
In the propensity score model, it was necessary to introduce
interaction terms to balance some of the variables. These interac-
tions were (1) age and pain, (2) CSQ reinterpretation and CSQ
diversion, (3) RMDQ at baseline and comorbidity (count of pre-
scribed nonanalgesic medications), and (4) NSAID prescription sta-
tus and distress. Once these 4 variables were included in the
propensity score model, balance was found across all variables,
and therefore the ﬁnal model included opioid prescription status
and propensity score group.
In the multivariable analysis, opioid prescription at baseline
predicted higher disability (RMDQ score) at 6 months (P = .022)
after adjusting for propensity score. The mean 6-month RMDQ
score was 1.18 (95% CI 0.17 to 2.19) units higher for those pre-
scribed opioids at baseline compared with those who were not pre-
scribed any opioids (Table 4).
4. Discussion
We observed a signiﬁcant association between receipt of an opi-
oid prescription in the baseline period and self-reported disability
at follow-up, even after adjusting for a large number of potentialprescription in baseline period Opioid prescription in baseline period
core Follow-up (6 months) Baseline score Follow-up (6 months)
9) 4.92 (5.18) 11.74 (6.11) 9.02 (7.24)
0) 2.77 (2.54) 5.79 (3.56) 4.21 (3.10)
7) 4.45 (3.79) 7.95 (4.60) 6.50 (4.89)
7) 6.09 (4.23) 9.16 (4.73) 7.72 (5.01)
.79) 43.97 (12.07) 31.79 (15.11) 34.46 (16.28)
Table 3
Unadjusted associations between baseline characteristics and disability at 6 months.
Baseline variable Regression
coefﬁcient*
95% conﬁdence
interval
Standardized regression
coefﬁcient (b)
P
value
Opioid prescription at baseline
Opioid prescription vs no opioid at baseline
4.21 3.28 to 5.09 0.32 <.001
Age
Per1-year increase
<0.01 0.04 to 0.05 <0.01 .884
Gender
Male vs female
0.80 1.73 to 0.14 0.06 .096
Social class
Professional/managerial vs lower occupation classiﬁcation
2.35 3.33 to 1.37 0.17 <.001
Education
Educated up to 16 years vs beyond 16 years
2.60 1.67 to 3.53 0.20 <.001
Work
Employed and working as usual vs unemployed/not working or working reduced hours
4.93 5.77 to 4.08 0.39 <.001
Usual pain intensity
Per 1-unit increase (Numerical Rating Scale, range 0–10)
1.09 0.94 to 1.25 0.46 <.001
Disability
Per 1-unit increase (Roland-Morris Disability Questionnaire, range 0–24)
0.706 0.65 to 0.76 0.67 <.001
Duration of pain
Duration >3 months vs 63 months)
4.75 3.85 to 5.64 0.63 <.001
Leg pain
Pain below the knee vs no leg pain below knee
3.75 2.84 to 4.67 0.29 <.001
Distress
Hospital Anxiety and Depression Questionnaire score P8 vs Hospital Anxiety and
Depression Questionnaire score <8 for anxiety and depression
5.09 4.18 to 6.01 0.38 <.001
Fear of movement
Per 1-unit increase (Tampa Scale of Kinesiophobia, range 17–68)
0.38 0.32 to 0.44 0.42 <.001
Self-efﬁcacy
Per 1-unit increase (Pain Self-Efﬁcacy Questionnaire, range 0–60)
0.26 0.28 to 0.23 0.59 <.001
Coping style
CSQ—diversion
Per 1-unit increase (range 0–36)
0.13 0.08 to 0.19 0.17 <.001
CSQ—catastrophizing
Per 1-unit increase (range 0–36)
0.41 0.36 to 0.46 0.51 <.001
CSQ—reinterpretation
Per 1-unit increase (range 0–36)
0.04 0.03 to 0.11 0.05 .221
CSQ—cognitive coping
Per 1-unit increase (range 0–30)
0.20 0.27 to 0.13 0.20 <.001
NSAID at baseline
NSAID prescription vs no NSAID at baseline
0.33 0.62 to 1.28 0.03 .498
Comorbidity
Per additional medication prescribed (nonopioid prescribed medication count)
0.71 0.52 to 0.89 0.27 <.001
Coefﬁcients from separate linear regressions.
CSQ = Coping Strategies Questionnaire; NSAID = nonsteroidal anti-inﬂammatory drug.
* Mean increase in follow-up Roland-Morris Disability Questionnaire score per unit change in independent variable.
 Statistically signiﬁcant P 6 .05.
Table 4
Unadjusted and adjusted associations between baseline opioid prescription and disability (RMDQ score) at 6 months.
Unadjusted analysis Adjusted analysis Multivariable analysis P value
Coefﬁcient* 95% CI Coefﬁcient* 95% CI Coefﬁcient* 95% CI
Opioid prescription in baseline period 4.21 3.28–5.14 1.23 0.45–2.00 1.18 0.17–2.19 .022
CI = conﬁdence interval; RMDQ = Roland-Morris Disability Questionnaire.
* Regression coefﬁcient denotes the mean difference in 6-month RMDQ score compared to a subject without an opioid prescription at baseline.
 Analysis adjusted for baseline RMDQ score.
 Multivariable model adjusted for propensity score.
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ated with receipt of an opioid prescription was small and therefore
unlikely to be clinically important [23]. Our ﬁndings imply, how-
ever, that receipt of an opioid prescription at baseline is not asso-
ciated with improved outcome.
Almost one third (32.7%) of patients with LBP in this study re-
ceived an opioid prescription within the baseline period, although
the majority of patients who received opioids were prescribed only
a low dose. The duration of opioid therapy either before or afterthe baseline period is unknown. Our ﬁndings indicate that patients
who received an opioid prescription in the baseline period differed
signiﬁcantly in their baseline characteristics from those who were
not prescribed opioids and that these differences were more marked
for those in the higher dose groups. Those prescribed opioids re-
ported higher pain intensity, including leg pain, and greater disabil-
ity, and were also more likely to receive medication for comorbid
conditions and to report higher distress, greater fear of movement,
a greater tendency to catastrophize, and lower self-efﬁcacy.
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for LBP is higher in this study than the 21.2% reported by Webster
et al. [36] in the United States and substantially higher than the
7.1% reported by Gross et al. [15] in Canada, although it is similar
to that found by Franklin et al. [14] in the United States. It is likely
that the variation in reported levels of opioid prescribing reﬂect
differences in study setting, methods, and population.
Our ﬁndings are consistent with those of previous studies
[14,15,36], which reported higher disability, as measured by con-
tinued receipt of wage replacement beneﬁts, in those who received
an early opioid prescription for LBP. However, these studies,
although they attempted to adjust for some measure of injury
severity and basic demographics, were not able to adjust for
important potential confounders, including psychosocial variables.
Gross et al. [15] found a similar association between prescribed
nonopioid analgesics and future disability, and concluded that
their ﬁndings were likely to be explained by pain severity or other
unmeasured confounders. It is perhaps surprising that in our study
the association between an opioid prescription at baseline and dis-
ability at follow-up remained signiﬁcant after adjusting for pain
intensity and a large number of other potential confounders,
whereas no signiﬁcant association was demonstrated between an
NSAID prescription and disability at follow-up, even in the unad-
justed analysis. It is difﬁcult to offer a plausible explanation, on
purely pharmacological grounds, for why opioids should be associ-
ated with greater disability even at very low doses, and although
we controlled for a substantial number of known and observed po-
tential confounders, we were not able to adjust for past history of
opioid use, smoking history, or the presence of all other painful
conditions, and the possibility of residual confounding by un-
known factors cannot be excluded.
The major strength of this study lies in combining the use of
electronic prescribing records with self-reported measures, allow-
ing us to accurately calculate the morphine equivalent dose and to
adjust for a large number of potential confounders, including pain
severity, nonopioid analgesic (NSAID) prescription, and psychoso-
cial variables. Other strengths of the study include its prospective
design, sample size, and unique primary care setting, which, in
the UK health service, is where most new episodes of LBP are
managed.
The use of a propensity score approach to adjust for multiple
confounders is more efﬁcient than a multivariable regression that
includes each variable separately. This leads to less bias in the esti-
mates and more generalizable results [28]. There was loss to fol-
low-up in the original cohort. The 715 participants included in
the sample had a slightly higher mean (SD) age than the original
study cohort and were slightly more likely to be female, but there
were no signiﬁcant differences in terms of key sociodemographic
characteristics, employment status, duration of back pain symp-
toms, or baseline pain and disability [13]. Given that responders
and nonresponders from the original study [13] were almost iden-
tical on key baseline characteristics, this offers some reassurance
regarding the likelihood of nonresponse bias, although the possi-
bility of unmeasured differences cannot be excluded.
We used electronic databases, which were likely to contain
complete data regarding all prescribed opioids. However, opioids
can be purchased in low doses without prescription in the UK,
and a potential limitation of our study is that it did not capture
the use of over-the counter opioid-containing medications.
Inequality in the number of subjects in each opioid dose group
and in particular the small numbers in the high-dose groups lim-
ited our ability to explore the effect of opioid dose on disability,
nor could we explore the effect of prescribed opioid use before
enrolment in the original study.
Our ﬁndings indicate that even after adjusting for a large num-
ber of covariates, receipt of an opioid prescription did not improvefunctional outcome from LBP. Furthermore, our ﬁndings suggest
that those who are prescribed opioids differ not only in terms of
the nature and intensity of reported pain but also in terms of
how they respond to that pain, as assessed by self-reported dis-
tress, self-efﬁcacy, and coping strategies. It is possible that these
and other responses may inﬂuence not only disability associated
with LBP, but also prescribing behavior of clinicians [31]. It is also
possible that patient preference for or against treatment with pre-
scribed opioid analgesics is associated with other differences in pa-
tient behavior in the presence of LBP, and that such differences
may in turn inﬂuence disability.
This study found that opioids were commonly prescribed for pa-
tients with LBP, and yet our ﬁndings and the previously published
literature in this ﬁeld provide little evidence that this is a useful
therapeutic strategy. Although individual randomized controlled
trials of opioid analgesics in LBP have demonstrated evidence of
short-term pain relief and modest functional improvement in
highly selected subjects with LBP, reviews [9,19] have highlighted
the lack of evidence for longer-term pain relief or clinically signiﬁ-
cant functional improvement. A further recent review [37] con-
cluded that in terms of efﬁcacy in LBP, opioids could not be
recommended as a ﬁrst-line treatment for LBP in view of their side
effect proﬁle, potential for tolerance with long-term use, and in the
absence of any evidence of superior efﬁcacy comparedwith NSAIDs.
However, it is likely that in recent years, concerns about cardiovas-
cular risk with certain NSAIDs have led to changes in prescribing
practice, including increased prescribing of opioid analgesics [2].
It is important that clinicians are aware that prescribing opioids
for LBP may not improve patient function. This may encourage clo-
ser monitoring of the response to opioid analgesics in terms of both
pain and function, providing the opportunity to discontinue where
there is no evidence of beneﬁt, and may encourage consideration of
alternative therapeutic strategies, including nonpharmacological
and psychologically based approaches.
Our ﬁndings raise a number of questions for future research. Pa-
tients with LBP represent a heterogeneous population, and it is
likely that response to opioids and other analgesic medications
may differ between subgroups [37]. It is possible that although
on average opioids do not improve function in LBP, this conceals
a range of responses, including some subjects who obtain func-
tional beneﬁts and others who have a poor response to opioids.
An important objective for future studies would be to identify
the subgroups of patients who might beneﬁt. Furthermore, identi-
fying the factors that inﬂuence a clinician’s decision to prescribe
opioids and a patient’s decision to take them might identify poten-
tial causal mechanisms for our ﬁndings. Pragmatic clinical trials in
real-life settings with long-term follow-up are required to inform
clinical decisions regarding the management of LBP. The incorpora-
tion of subgroup analysis into such trials may further aid the devel-
opment of clinical recommendations for the management of this
heterogeneous patient group.5. Conﬂict of interest
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